Application describes a proposed architecture integrating space-based sensing, artificial intelligence, resilient HF communications, secure command and control, and coordinated multi-effector defense against drones and autonomous aerial threats; ARGUS remains in development, and no patent has been issued

WEST HOLLYWOOD, Calif., Sept. 14, 2026 (GLOBE NEWSWIRE) — VisionWave Holdings, Inc. (Nasdaq: VWAV) (“VisionWave” or the “Company”), an advanced defense technology company specializing in artificial intelligence, autonomous systems, RF sensing, and next-generation defense technologies, today announced that it has filed a U.S. non-provisional patent application with the U.S. Patent and Trademark Office (the “USPTO”) describing ARGUS™, a proposed space-enabled, AI-driven counter-unmanned aircraft system (C-UAS) architecture that the Company is developing.

The U.S. patent application, Serial No. 19/797,497, filed on September 4, 2026, 2026, is titled “Systems and Methods of Detecting and Countering Drone Attacks by Space-Enabled, AI-Driven Counter-UAS Architecture.” The application claims priority to U.S. provisional patent application Serial No. 63/940,940, filed on December 15, 2025, and describes an integrated architecture intended to detect, classify, track, evaluate, and respond to hostile drones and other low-altitude aerial threats over wide geographic areas. The application has not yet been examined by the USPTO. Patent applications are frequently rejected or allowed only with claims narrower than those originally filed, and there can be no assurance that any patent will issue from the application, that the scope of any issued claims will be the same as the claims as filed, or that any patent that issues will provide VisionWave with a competitive advantage or withstand challenge.

As described in the application, ARGUS is intended to combine space-based surveillance, artificial intelligence, ground-based sensing, resilient communications, cybersecurity, command and control, and multiple types of defensive effectors into a coordinated counter-UAS system.

ARGUS is an architecture described in a pending patent application and remains in development. ARGUS has not been built, integrated or tested as a system, and no prototype of the complete architecture exists. VisionWave does not own or operate any satellites and has no agreement with any satellite operator, launch provider, government agency or other party for the space segment or any other element of ARGUS. The capabilities described in this press release are those set out in the application; they have not been demonstrated or independently validated. Developing, testing and fielding ARGUS would require substantial additional capital, third-party participation and government authorizations, none of which is assured, and ARGUS has not generated any revenue.

The patent application describes a space segment incorporating satellites equipped with electro-optical and infrared sensors, with optional synthetic aperture radar and RF sensing capabilities, intended to provide wide-area surveillance and early detection. Under the described architecture, information collected from space would be combined with information from ground-based radar, RF, and EO/IR sensors to form a unified recognized air picture.

A central element of the described architecture is an AI-based object-recognition methodology designed to analyze the structural geometry of airborne objects. Rather than relying solely on conventional image classification, the methodology described in the application is designed to identify structural key points such as rotor hubs, arms, fuselage features, wings, and payload attachment points and to use multi-view information to generate virtual three-dimensional representations of potential targets. This approach is intended to improve classification where a target is partially obscured or observed from difficult viewing angles; its performance has not been validated through testing

The application also describes multi-sensor fusion and AI-based threat assessment, combining information from satellites, radar, RF detectors, EO/IR sensors, and other sources. The described system is designed to update target tracks and threat scores continuously as additional evidence becomes available and to use those assessments within command-and-control logic to determine whether an object should be monitored, generate a warning, or be considered for engagement, with any engagement subject to authorization by a human operator.

Another component of the disclosed architecture is SkyWeave™, an AI-controlled high-frequency (HF) communications backbone, also in development, designed to provide resilient beyond-line-of-sight command and control. As described in the application, the HF network would dynamically evaluate ionospheric conditions, interference, link quality, mission requirements, and other factors to select frequencies, transmission power, antenna configurations, relay nodes, and communications routes. The architecture is intended to maintain command connectivity when SATCOM, cellular, microwave, or terrestrial communications are degraded, jammed, or unavailable.

The application also describes a security architecture for protecting command, communications, and navigation information, including authentication, encryption, session security, key establishment, and synchronous or asynchronous key-exchange techniques designed for constrained and intermittently available communications environments.

The described system is designed to coordinate a layered mix of defensive responses rather than depend upon a single interceptor technology. Depending upon mission conditions, threat assessment, communications availability, rules of engagement, and collateral-risk considerations, the architecture described in the application would coordinate interceptor drones, RF jammers, deceptive navigation techniques, kinetic systems, directed-energy systems, high-power microwave systems, and other effectors. In the United States, the use of RF jamming, navigation spoofing and certain other counter-UAS mitigation technologies is restricted by federal law and is generally limited to specifically authorized government agencies, and similar restrictions apply in many other jurisdictions. These restrictions may limit the potential customers for, and permitted uses of, ARGUS.

“ARGUS represents our vision for moving counter-drone defense toward an intelligent, distributed defense architecture,” said Danny Rittman, Chief Technology Officer of VisionWave. “The objective is to connect detection, artificial intelligence, resilient communications, cybersecurity, command and control, and multiple defensive technologies into a single coordinated system. By combining space-based awareness with terrestrial sensors and resilient HF communications, ARGUS is being designed for the increasingly contested environments in which we believe future counter-UAS systems will need to operate.”

The patent application additionally describes predictive trajectory modeling and defensive swarm concepts. Under the described approach, AI models would forecast likely target positions and behavior, allowing defensive assets to be positioned along predicted ingress corridors, and the architecture would coordinate defensive drones using global sensor information, resilient HF communications, encrypted navigation information, and local autonomous control.

VisionWave believes the filing is a step in the development of ARGUS and is consistent with the Company’s broader strategy of developing AI-enabled, resilient, and distributed defense technologies intended to operate across space, RF, cyber, autonomous, and physical domains.

About ARGUS™

ARGUS™ is a proposed space-enabled counter-UAS architecture, in development by VisionWave and described in a pending U.S. patent application, that is designed to integrate wide-area sensing, artificial intelligence, multi-sensor fusion, resilient communications, secure command and control, and layered countermeasure technologies. The architecture is intended to support defense against small unmanned aircraft, autonomous aerial systems, loitering munitions, and coordinated drone threats across geographically distributed operating environments. ARGUS has not been commercialized, is not available for sale and has not generated any revenue.

About VisionWave Holdings, Inc.

VisionWave Holdings, Inc. (Nasdaq: VWAV) is a defense and advanced sensing technology company developing AI-driven, RF-based sensing, autonomy, and computational acceleration technologies for defense, homeland security, and commercial infrastructure applications. VisionWave’s mission is to connect defense innovation with civilian progress through shared core technologies deployed across air, land, and fixed-site environments. The Company’s website is https://www.vwav.inc. Information contained on, or accessible through, the Company’s website is not incorporated by reference into, and does not form a part of, this press release or any filing of the Company with the Securities and Exchange Commission.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, and such statements are intended to be covered by the safe harbor provisions of those laws. All statements other than statements of historical fact are forward-looking statements, including statements regarding the prosecution of U.S. Patent Application Serial No. 19/797,497 and the scope of any patent that may issue from it; the design, development, capabilities, testing, performance, potential applications, commercialization and future deployment of ARGUS, SkyWeave and other VisionWave technologies; the Company’s ability to obtain the satellite, communications, effector and other capabilities, third-party participation and government authorizations that the ARGUS architecture contemplates; and the Company’s business strategy. Forward-looking statements are generally identified by words such as “anticipate,” “believe,” “continue,” “could,” “designed to,” “estimate,” “expect,” “intend,” “intended to,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “vision,” “will,” “would” and similar expressions, although not all forward-looking statements contain these identifying words.

Forward-looking statements are based on management’s current expectations and assumptions and are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied, including, among others: the risk that the USPTO rejects the application or allows only claims narrower than those sought, that any patent that issues is challenged, invalidated or circumvented, or that third parties hold patents that the ARGUS architecture would infringe; the early stage of development of ARGUS and SkyWeave, which have not been built or tested as integrated systems and may never be successfully developed; the Company’s need for substantial additional capital to develop ARGUS and its other technologies, which may not be available on acceptable terms or at all, and the dilution that may result from equity financings, including sales under the Company’s at-the-market offering programs, conversions of outstanding convertible debentures and exercises of outstanding warrants; the Company’s dependence on third parties for satellites, launch services, space-based data, effectors and other elements that it does not own or produce; legal restrictions on the use of RF jamming, navigation spoofing, directed-energy and other counter-UAS mitigation technologies, and the need for spectrum, export and other governmental authorizations; U.S. export control laws and regulations, including the International Traffic in Arms Regulations and the Export Administration Regulations, and any secrecy order that may be imposed with respect to the application; the lengthy, uncertain and budget-dependent nature of government procurement, and the absence of any contract or award for ARGUS; competition from larger, better-capitalized defense contractors; the performance and reliability of artificial-intelligence models; cybersecurity risks; the Company’s limited operating history and revenue, history of losses and the substantial doubt about its ability to continue as a going concern; the Company’s ability to maintain compliance with The Nasdaq Stock Market’s continued listing requirements, including the minimum bid price requirement; and the other risks described under “Risk Factors” in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2025, its subsequent Quarterly Reports on Form 10-Q and its other filings with the Securities and Exchange Commission, available at www.sec.gov.

Forward-looking statements speak only as of the date of this press release and are expressly qualified in their entirety by these cautionary statements. Readers should not place undue reliance on forward-looking statements. VisionWave undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by applicable law.

Contact for Investors: investors@vwav.inc

CALGARY, Alberta, Sept. 14, 2026 (GLOBE NEWSWIRE) — Canadian Premium Sand Inc. (“CPS” or the “Company”) (TSXV: CPS) is pleased to announce that it is participating in the inaugural Canada Investment Summit (the “Summit”) hosted by Prime Minster Mark Carney on September 14th and 15th in Toronto, Ontario, providing the Company with an exceptional opportunity to engage with leading institutional investors from around the world and to demonstrate how CPS can contribute to long-term economic growth while delivering value to shareholders, stakeholders, partners and the communities in which we operate.

The Company’s proposed vertically integrated 600 tonne per day float glass manufacturing facility in Selkirk, Manitoba utilizing its wholly owned low-iron silica sand resource (the “Project”) will be included in the Summit prospectus for distribution to all Summit participants.

“We are honoured to be included in the prospectus for the inaugural Canada Investment Summit,” said Glenn Leroux, President & CEO of CPS. “Canada is currently 100% reliant on imported float glass to support 30,000 jobs and a $2 billion industry. Our Project can reduce this dependency by providing Canada with a secure domestic supply of high-quality glass and set a foundation to build a more diversified glass industry in Canada. With established Indigenous and local community partnerships, a wholly owned unique silica resource and permitted projects, the CPS Project represents an important nation-building opportunity for Canada.”

The Company’s project is also included in the Manitoba Deal Book promoted at the Summit by Premier Wab Kinew. Participants at the Summit include large international investors and sovereign wealth funds, along with private equity firms and sources of public capital.

On September 15th, the Company is also participating in a roundtable on critical minerals hosted by Dentons and Invest in Alberta, in association with the Province of Manitoba. The roundtable will focus on a range of topics structured to drive discussion on how critical minerals projects can attract financing.

As part of the Company’s ongoing strategic review announced earlier this year, one of the development options the Company has advanced through the process is the manufacturing of float glass for use in residential and commercial buildings. With no current manufacturing of float glass in Canada, the Project is critical in enabling the domestic industry to secure independence from US imports. The Company is working to secure offtakes with the Canadian customer base sufficient to support financing the Project.

About Canada Investment Summit

The Summit is hosted by Prime Minister Mark Carney in partnership with Canada Pension Plan Investment Board and Public Sector Pension Investment Board, two of Canada’s largest institutional investors. The Summit is part of the Government of Canada’s broader objective to catalyze $1 trillion of total investment in Canada over the next five years, including investment that expands domestic manufacturing, creates good, long-term jobs and strengthens Canadian supply chains.

Structured as a practical forum, the Summit is focused on long-horizon capital, commercial opportunity and productive assets that strengthen growth and resilience. To help advance projects like the Project, the Summit aims to mobilize long term capital, create high-quality jobs, strengthen global supply-chain integration and enhance Canada’s competitiveness and economic resilience.

About Canadian Premium Sand Inc.

Canadian Premium Sand Inc. is developing its Wanipigow silica sand resource in Manitoba to supply high specification, high purity, low iron silica sand for vertically integrated manufacturing of float glass and solar glass, fracture proppant for the Western Canada Sedimentary Basin, and a range of other industrial and manufacturing applications. The Company is a reporting issuer in Ontario, Alberta and British Columbia. Its shares trade on the TSX Venture Exchange under the symbol “CPS”.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

 
CONTACT INFORMATION:
 
Canadian Premium Sand Inc. 
Glenn Leroux
President and Chief Executive Officer
glenn.leroux@cpsmail.com
 
Investor Relations
IR@cpsmail.com
587.355.3714
https://cpsglass.com  
 

Forward-Looking Information

Certain statements contained in this press release constitute forward-looking statements relating to, without limitation, expectations, intentions, plans and beliefs, including information as to the future events, results of operations and the Company’s future performance (both operational and financial) and business prospects. In certain cases, forward-looking statements can be identified by the use of words such as “expects”, “estimates”, “forecasts”, “intends”, “anticipates”, “believes”, “plans”, “seeks”, “projects” or variations of such words and phrases, or state that certain actions, events or results “may” or “will” be taken, occur or be achieved. Such forward-looking statements reflect the Company’s beliefs, estimates and opinions regarding its future growth, results of operations, future performance (both operational and financial), and business prospects and opportunities at the time such statements are made, and the Company undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or circumstances should change. Forward-looking statements are necessarily based upon a number of estimates and assumptions made by the Company that are inherently subject to significant business, economic, competitive, political, geopolitical and social risks, uncertainties and contingencies and the other risk factors outlined in CPS’s most recent Management’s Discussion and Analysis which is available on SEDAR+ at www.sedarplus.ca. Forward-looking statements are not guarantees of future performance. In particular, this press release contains forward-looking statements pertaining, but not limited, to: the purpose and goal of CPS attending the Summit and the potential benefits to be derived therefrom including the ability to engage with investors to demonstrate to attendees how CPS can contribute to long-term economic growth while delivering value to shareholders, stakeholders, partners and the communities in which we operate; the ability to finance the Project including obtaining offtake agreements for this purpose; and the Company’s objectives, strategies and competitive strengths. By their nature, forward-looking statements involve numerous current assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to differ materially from those anticipated by the Company and described in the forward-looking statements. The forward-looking information and statements contained in this document speak only as of the date hereof and the Company does not assume any obligation to publicly update or revise them to reflect new events or circumstances, except as may be required pursuant to applicable laws.

Hop Valley opens its new pub Sept. 17, giving Ducks fans a new place to rally, celebrate, and raise a pint on game day

Hop Valley Eugene Bar

EUGENE, Ore., Sept. 14, 2026 (GLOBE NEWSWIRE) — Hop Valley Brewing Co, a trailblazer in the craft brewing industry and a brand by Tilray Brands, Inc. (NASDAQ: TLRY and TSX: TLRY), today announced it will open a new pub at 5th Street Public Market in downtown Eugene, pouring its first pint at 5:30 p.m. on Thursday, Sept. 17.

The sports-forward brewpub returns Hop Valley to Eugene, serving the brewery’s award-winning beers alongside a full food menu and screens for every Ducks game. The tap list features fan favorites including Dang Green IPA, the first officially licensed, co-branded craft beer of the Oregon Ducks.

To mark the opening, Hop Valley will host a pre-game rally on Thursday, Sept. 17 ahead of the Ducks’ home game against Portland State. The celebration will include appearances by the Oregon Ducks mascot and cheer squad, merchandise and ticket giveaways, and a live DJ. The first 100 guests, 21 and over, will receive custom Oregon Ducks x Hop Valley glassware. A group Dang Green toast at 6 p.m. will lead into a celebration that runs until the pub closes at 9 p.m.

“We’re thrilled to welcome the Eugene community back to raise a pint with us in the heart of downtown,” said Brian Hughes, Senior Director, Brands West at Tilray Beverages. “Hop Valley was built here, and this space was designed to feel like a true local hangout, somewhere fans, friends and neighbors can gather all year long. With our longstanding partnership with the Ducks, there’s no better way to open our doors.”

Founded in Springfield in 2009, Hop Valley has been part of the Eugene-Springfield community for more than 15 years. The 5th Street pub joins Hop Valley’s Springfield location and gives the brewery a downtown Eugene home base for Ducks fans, craft beer lovers and community events year-round.

Event Details

  • What: Grand opening of Hop Valley Brewing Co.’s new Eugene pub
  • When: Ducks pre-game rally Sept. 17, 4:30–9 p.m., with a group Dang Green toast at 6 p.m.
  • Where: 5th Street Public Market, 550 Pearl St Suite 150, Eugene, OR 97401

Follow @hopvalleybrewing on Instagram and visit hopvalleybrewing.com for opening updates, events, and tap list details.

About Hop Valley Brewing

Founded in 2009 in the most free-spirited city in a state known for innovation and high-quality hops, Hop Valley Brewing proudly embraces the influences of our counter-culture surroundings in the crafting of refreshingly different beers.

About Tilray Brands

Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), is a leading global lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America that is leading as a transformative force at the nexus of cannabis, beverage, wellness, and entertainment, elevating lives through moments of connection. Tilray’s mission is to be a leading premium lifestyle company with a house of brands and innovative products that inspire joy and create memorable experiences. Tilray’s unprecedented platform supports over 40 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods, and craft beverages.

For more information on how we are elevating lives through moments of connection, visit Tilray.com and follow @Tilray on all social platforms.

Forward-Looking Statements

Certain statements in this communication that are not historical facts constitute forward-looking information or forward-looking statements (together, “forward-looking statements”) under Canadian and U.S. securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the “safe harbor” created by those sections and other applicable laws. Forward-looking statements can be identified by words such as “forecast,” “future,” “should,” “could,” “enable,” “potential,” “contemplate,” “believe,” “anticipate,” “estimate,” “plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, goals, projections, or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses, or current expectations. Many factors could cause actual results, performance, or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of Tilray and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of Tilray made with the SEC and available on EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events, or otherwise unless required by applicable securities law.

For further information, please contact:

Tilray Brands Media: news@tilray.com

Tilray Brands Investors: investors@tilray.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/517c2566-aec2-4f15-87d3-d53065f86ec0

Independent DSMB Recommends MediWound’s EscharEx® Phase III VALUE Study Continue Without Modification

DSMB did not identify safety concerns in pre-specified review; interim assessment and enrollment completion remain on track for end of the first quarter of 2027

YAVNE, Israel, September 14, 2026 (GLOBE NEWSWIRE) — MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that the independent Data and Safety Monitoring Board (DSMB) completed its pre-specified periodic safety review of the ongoing Phase III VALUE study evaluating the safety and efficacy of EscharEx® in patients with venous leg ulcers (VLU). Following its review, the DSMB did not identify any safety concerns and recommended that the study continue as planned without modification. MediWound also continues to expect the study’s pre-specified interim sample-size reassessment and completion of patient enrollment by the end of the first quarter of 2027.

“We are encouraged by the DSMB’s recommendation to continue the VALUE study as planned and without modification,” said Ofer Gonen, Chief Executive Officer of MediWound. “The DSMB’s findings are consistent with the favorable safety profile observed across the EscharEx clinical program and support our continued execution of this pivotal Phase III study.”

About the VALUE Trial

VALUE (NCT06568627) is a global, multicenter, randomized, double-blind, placebo-controlled Phase III pivotal trial evaluating the efficacy and safety of EscharEx® in patients with venous leg ulcers (VLU). The study is designed to enroll 216 patients across approximately 40 sites in the U.S., Europe, and Israel, randomized in a 1:1 ratio to receive EscharEx or placebo. The co-primary endpoints are the incidence of complete debridement and the facilitation of wound closure. The study includes a pre-specified interim sample-size reassessment after 65% of patients have completed the 12-week wound-management period. The interim reassessment and completion of enrollment are expected by the end of the first quarter of 2027. An independent DSMB separately conducts pre-specified periodic reviews that address safety only.

About EscharEx®

EscharEx is a bromelain-based, bioactive enzymatic therapy in advanced clinical development for the debridement of chronic and hard-to-heal wounds. Designed for topical, once-daily use, EscharEx has demonstrated effective wound bed preparation and a favorable safety profile in multiple Phase II studies. It enables rapid removal of non-viable tissue while promoting granulation tissue formation and reducing bioburden and biofilm. The global Phase III VALUE trial in venous leg ulcers (VLU) is underway, with additional clinical studies planned in diabetic foot ulcers (DFU) and pressure ulcers (PU). EscharEx has demonstrated advantages over standard-of-care treatments, including the leading enzymatic debridement agent, and targets a substantial global market opportunity.

About MediWound Ltd.

MediWound Ltd. (Nasdaq: MDWD) is a global leader in next-generation enzymatic therapeutics for tissue repair. The company’s FDA-approved biologic, NexoBrid®, is indicated for the enzymatic removal of eschar in thermal burns and is marketed in the United States, the European Union, Japan, and additional international markets. MediWound’s late-stage development candidate, EscharEx®, is an investigational therapy for the debridement of chronic wounds, with the potential to become a new standard of care in wound management.

For more information, visit www.mediwound.com and follow us on LinkedIn and X (formerly Twitter).

Cautionary Note Regarding Forward-Looking Statements

MediWound cautions you that all statements other than statements of historical fact included in this press release that address activities, events, or developments that we expect, believe, or anticipate will or may occur in the future are forward-looking statements. Although we believe that we have a reasonable basis for the forward-looking statements contained herein, they are based on current expectations about future events affecting us and are subject to risks, assumptions, uncertainties, and factors, all of which are difficult to predict and many of which are beyond our control. Actual results may differ materially from those expressed or implied by the forward-looking statements in this press release. These statements are often, but are not always, made through the use of words or phrases such as “anticipates,” “intends,” “estimates,” “plans,” “expects,” “continues,” “believe,” “guidance,” “outlook,” “target,” “future,” “potential,” “goals” and similar words or phrases, or future or conditional verbs such as “will,” “would,” “should,” “could,” “may,” or similar expressions.
Specifically, this press release contains forward-looking statements concerning the anticipated progress, development, study design, expected data timing, objectives, anticipated timelines, outcome of future periodic DSMB’s reviews, expectations and commercial potential of our products and product candidates, including EscharEx®. Among the factors that may cause results to be materially different from those stated herein are the inherent uncertainties associated with the uncertain, lengthy and expensive nature of the product development process; the timing and conduct of our studies of our products and product candidates, including the timing, progress and results of current and future clinical studies, and our research and development programs; the approval of regulatory submission by the FDA, the European Medicines Agency or by any other regulatory authority, our ability to obtain marketing approval of our products and product candidates in the U.S. or other markets; our contracts with governmental agencies; the clinical utility, potential advantages and timing or likelihood of regulatory filings and approvals of our products and product candidates; our expectations regarding future growth, including our ability to develop new products; market acceptance of our products and product candidates; our ability to maintain adequate protection of our intellectual property; competition risks; geopolitical risks, including armed conflict, the need for additional financing; the impact of government laws and regulations and the impact of the current global macroeconomic climate on our ability to source supplies for our operations or our ability or capacity to manufacture, sell and support the use of our products and product candidates in the future. These and other significant factors are discussed in greater detail in MediWound’s annual report on Form 20-F for the year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on March 5, 2026 and Quarterly Reports on Form 6-K and other filings with the SEC from time-to-time. These forward-looking statements reflect MediWound’s current views as of the date hereof and MediWound does not undertake, and specifically disclaims, any obligation to update any of these forward-looking statements to reflect a change in their respective views or events or circumstances that occur after the date of this release except as required by law.

MediWound Contacts:      
Hani Luxenburg
Chief Financial Officer
MediWound Ltd.
ir@mediwound.com
  Daniel Ferry
Managing Director
LifeSci Advisors, LLC
daniel@lifesciadvisors.com
 

Appointments strengthen rare-disease commercialization planning and strategic partnering capabilities as Ebstrocel™ advances toward potential commercialization

BOCA RATON, Fla., Sept. 14, 2026 (GLOBE NEWSWIRE) — INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced the appointments of R. Duane Clark II and James Sapirstein, R.Ph., MBA, to its Board of Directors. The appointments add commercial and strategic operating expertise as INmune Bio prepares Ebstrocel™ for potential rare-disease commercialization and pursues business-development and partnering opportunities across its pipeline.

Mr. Clark brings more than 40 years of global pharmaceutical and biotechnology leadership, with particular depth in rare diseases, immunology and specialty-product commercialization. He currently serves as General Manager, U.S. Rare Diseases at Sanofi, where he leads a multi-billion-dollar business spanning seven rare-disease brands with full profit-and-loss responsibility. His experience includes multiple product launches, market-access strategy, M&A integration, and leadership across sales, marketing, medical and commercial operations. Earlier in his career, he led Sanofi’s U.K. and Ireland multiple sclerosis business and held commercial and business-development roles at CTI Clinical Trial & Consulting Services, Encysive Pharmaceuticals, Astellas Pharma, Ortho Biotech and Marion Laboratories.

Mr. Sapirstein brings more than 40 years of biopharmaceutical leadership spanning business development, licensing, commercialization, capital formation and public-company leadership experience. He has led six global commercial product launches and participated in more than 20 additional launches. His career includes senior roles at Gilead Sciences, Bristol Myers Squibb, Hoffmann-La Roche, Eli Lilly and Serono Laboratories. He also founded and led Tobira Therapeutics, which was later acquired by Allergan in a transaction with total potential consideration of up to approximately $1.7 billion, including contingent milestone payments. Mr. Sapirstein also brings extensive experience structuring strategic transactions and guiding biotechnology companies through growth, restructuring, and value-creating exits.

“These appointments bring capabilities directly aligned  with INmune Bio’s next stage of growth,” said David Moss, Chief Executive Officer of INmune Bio. “Duane’s rare-disease leadership leading a major rare-disease business will strengthen our planning for market access and potential commercialization of Ebstrocel. James’s business development, licensing, and financing experience will support our evaluation of strategic opportunities for our broader pipeline. Together, they add practical experience to help us translate development progress into potential patient and shareholder value.”

The new directors strengthen the Board in:

  • Rare-disease commercialization: Guide market access and pricing, patient identification, commercial infrastructure and launch execution for Ebstrocel™ in recessive dystrophic epidermolysis bullosa (RDEB) and potential additional rare-disease indications.
  • Business development and strategic transactions: Strengthen the evaluation and negotiation of licensing, distribution, co-development and other strategic relationships intended to accelerate development and broaden commercial reach.
  • Commercial scale and execution: Help align clinical, regulatory, manufacturing and commercial functions as INmune Bio advances from late-stage development toward potential product launches.

“Ebstrocel has the potential to address important unmet needs in rare disease, and INmune Bio is approaching the stage at which disciplined launch and market-access planning can become a meaningful competitive advantage,” said Mr. Clark. “I look forward to helping the Company build a patient-focused commercialization strategy and the capabilities required to execute it.”

“INmune Bio has multiple opportunities to create value through focused internal development and well-structured strategic partnerships,” said Mr. Sapirstein. “I look forward to contributing my business-development, transaction and commercialization experience as the Company evaluates the best path to advance its differentiated platforms.”

About INmune Bio Inc.

INmune Bio Inc. is a publicly traded (NASDAQ: INMB), late-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. The Company’s clinical-development strategy centers on advanced precision medicine, matching drug mechanisms directly to patient biology to optimize clinical outcomes.

INmune Bio is actively advancing two late-stage product platforms toward registrational milestones:

  • CORDStrom™: A proprietary, pooled, allogeneic, human umbilical cord-derived mesenchymal stromal cell platform engineered to address the historical clinical challenges of donor variability and manufacturing inconsistency. Following successful clinical readouts in RDEB, the platform is transitioning to regulatory filing phases, with an MAA planned for the UK MHRA in 2026 and EU EMA in 2027, alongside a planned U.S. Biologics License Application (BLA) submission.
  • XPro1595™: A Dominant-Negative Tumor Necrosis Factor (DN-TNF) platform designed to selectively neutralize soluble TNF (sTNF) and reduce neuroinflammation without compromising protective immune function. Backed by recently granted FDA Fast Track designation and successful regulatory alignment from an End-of-Phase 2 meeting, XPro1595™ is positioned for an integrated Phase 2b/3 seamless adaptive registrational program in neuroinflammation-enriched early Alzheimer’s disease.

To learn more about INmune Bio’s pipeline and its approach to harnessing the innate immune system, please visit www.inmunebio.com.

Forward Looking Statements

The Company’s product candidates remain in clinical development stage and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release related to the development or commercialization of product candidates and other business and financial matters, including without limitation, trial results and data, including  Ebstrocel™, XPro™ and INKmune™ trial results, timing of key milestones, future plans or expectations, and the prospects for receiving regulatory approval or commercializing or selling any product or drug candidates, may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to several risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements because of these risks and uncertainties. CORDStrom™, XPro1595™ (XPro™, pegipanermin), and INKmune™ have either finished clinical trials, are still in clinical trials or are preparing to start clinical trials and have not been approved by the US Food and Drug Administration (FDA), the UK MHRA or any regulatory body and there cannot be any assurance that they will be approved by the FDA, the UK MHRA or any regulatory body or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements to reflect any event or circumstance that may arise after the date of this release.

INmune Bio Contacts:

David Moss 
Chief Executive Officer 
(561) 710-0512 
info@inmunebio.com

Daniel Carlson 
Head of Investor Relations 
(415) 509-4590 
dcarlson@inmunebio.com

SANTA MONICA, Calif., Sept. 14, 2026 (GLOBE NEWSWIRE) — The Macerich Company (NYSE: MAC) today announced that Jackson Hsieh, President and Chief Executive Officer, Dan Swanstrom, Senior Executive Vice President and Chief Financial Officer and Treasurer, and Doug Healey, Senior Executive Vice President Leasing, will present to and speak with investors at BofA Securities 2026 Global Real Estate Conference in New York, NY September 15-16, 2026.

Macerich will present at 12:45 p.m. Eastern on Wednesday, September 16, 2026. The live audio webcast and a copy of the presentation can be accessed from the Company’s website at https://investing.macerich.com. The webcast replay will be available within 24 hours after conclusion of the live event and available at the same location for one year.

About Macerich
Macerich (NYSE: MAC) is a fully integrated, self-managed, self-administered real estate investment trust (REIT). As a leading owner, operator, and developer of high-quality retail real estate in densely populated and attractive U.S. markets, Macerich’s portfolio is concentrated in California, the Pacific Northwest, Phoenix/Scottsdale, and the Metro New York to Washington, D.C. corridor. Developing and managing properties that serve as community cornerstones, Macerich currently owns approximately 40 million square feet of real estate, consisting primarily of interests in 38 retail centers.
 
Macerich uses, and intends to continue to use, its Investor Relations website, which can be found at investing.macerich.com, as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Additional information about Macerich can be found through social media platforms such as LinkedIn. Reconciliations of non-GAAP financial measures, including NOI and FFO, to the most directly comparable GAAP measures are included in the earnings release and supplemental filed on Form 8-K with the SEC, which are posted on the Investor Relations website at investing.macerich.com.

INVESTOR CONTACT: Investor Relations, IR@macerich.com

TORONTO, Sept. 14, 2026 (GLOBE NEWSWIRE) — NexGold Mining Corp. (TSXV: NEXG; OTCQX: NXGCF) (“NexGold” or the “Company”) is pleased to announce that its fully permitted Goldboro Gold Project in Nova Scotia has been selected for inclusion in the Canada Investment Summit Prospectus, which will be given to leading global investors at the inaugural Canada Investment Summit, hosted by Prime Minister Mark Carney in partnership with CPP Investments and PSP Investments, in Toronto on September 14-15, 2026.

Kevin Bullock, President, CEO & Director of NexGold, commented: “I am honoured on behalf of NexGold to see the Goldboro Gold Project showcased in the Canada Investment Summit Prospectus, which will be presented to some of the world’s largest long-horizon institutional investors and prominent business leaders. Goldboro’s inclusion in the Summit Prospectus speaks not only to the quality of the Project from an investment standpoint but is also a testament to the hard work of our team in advancing the Project, while building strong relationships with local communities and First Nations. As a Canadian company advancing a portfolio of Canadian projects toward production, we are proud to have the Goldboro Gold Project featured among the projects highlighted at this high-profile global event.”

About the Goldboro Gold Project

NexGold is steadily advancing its fully permitted Goldboro Gold Project in Nova Scotia. The Company is evaluating a potential construction decision for Goldboro, which is currently anticipated in 2026. The Goldboro Gold Project is located in Guysborough County, Nova Scotia, approximately 1.6 km north of the Village of Goldboro. Situated along Route 316, the Project benefits from access to world class infrastructure, services and a skilled workforce, supporting efficient future development activities. Based on the Project’s 2022 Mineral Resource Estimate, Goldboro contains an estimated 2.58 million ounces of gold within 21.6 million tonnes grading 3.72 g/t gold. According to the Goldboro Feasibility Study, the Project is expected to have a mine life of approximately 11 years and average annual gold production of approximately 100,000 ounces during the initial years of operation, with potential opportunities for future expansion.

About the Canada Investment Summit

The inaugural Canada Investment Summit will take place in Toronto on September 14-15, 2026. Hosted by the Prime Minister of Canada in partnership with CPP Investments and PSP Investments, the Summit will convene the world’s largest investors, including top CEOs, entrepreneurs, and prominent global business leaders for a two-day forum focused on long-horizon capital, commercial opportunities and productive assets that strengthen Canada’s growth and economic resilience. The Summit forms part of the Government of Canada’s broader effort to strengthen Canada’s investment environment, diversify trade and attract approximately $1 trillion in total investment in Canada over the next five years.

For additional information on the Canada Investment Summit: Canada Investment Summit 2026.

Qualified Person

Paul McNeill, P.Geo., VP Exploration of NexGold, and a “Qualified Person” as defined by National Instrument 43-101 – Standards of Disclosure for Mineral Projects, has reviewed and approved the scientific and technical information contained in this news release.

About NexGold Mining Corp.
NexGold is a gold-focused company with assets in Canada and Alaska, including the Goldboro Gold Project in Nova Scotia, the Goliath Gold Complex (which includes the Goliath, Goldlund and Miller deposits) in Northwestern Ontario, and additional exploration projects across Canada. NexGold also holds a 100% interest in the high-grade Niblack copper-gold-zinc-silver VMS project in southeast Alaska. NexGold is committed to ongoing, meaningful engagement with regional communities and Indigenous Nations to support sustainable development, safe operations, and shared economic and social benefits.

Further details about NexGold, including a Feasibility Study for the Goldboro Gold Project and a Prefeasibility Study for the Goliath Gold Complex, are available under the Company’s issuer profile on www.sedarplus.ca and on NexGold’s website at www.nexgold.com.

Contact:

Kevin Bullock
President & CEO
(416) 214-4654
kbullock@nexgold.com
Greg DiTomaso
Investor Relations
(647) 547-5357
gditomaso@nexgold.com
   

Cautionary Note Regarding Forward-Looking Information

This news release contains “forward-looking information” within the meaning of applicable Canadian securities legislation and “forward-looking statements” within the meaning of applicable U.S. securities laws (collectively, “forward-looking information”). Forward-looking information includes, but is not limited to, statements regarding: the advancement and development of the Goldboro Gold Project; the timing of a potential construction decision; future construction, financing and development activities; the Project’s anticipated mine life and production profile; potential future expansion opportunities; the Company’s participation in, and potential benefits arising from, the Canada Investment Summit; and the Company’s plans, objectives and expectations for its projects. All statements, other than statements of historical fact, are forward-looking.

Forward-looking information is often, but not always, identified by the use of words and phrases such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “projects”, “anticipates”, “believes”, “targets”, “potential”, “may”, “could”, “should”, “would”, “will” and similar expressions.

Forward-looking information is based on a number of assumptions, including, among others, assumptions regarding financing availability, commodity prices, operating and capital cost estimates, market conditions, the timing of regulatory, corporate and Board approvals, the continued advancement of the Goldboro Gold Project, and the accuracy of technical studies and Mineral Resource estimates. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those expressed or implied by such forward-looking information. These risks and uncertainties include, among others: the ability of the Company to obtain financing on acceptable terms or at all; risks associated with the development and construction of mineral projects; changes in commodity prices and market conditions; operating and capital cost increases; environmental, community, Indigenous, permitting and regulatory risks; delays in obtaining approvals or completing development activities; labour shortages; and the other risks described in the Company’s public disclosure documents, including its Management’s Discussion and Analysis for the year ended December 31, 2025, available under the Company’s profile on SEDAR+ at www.sedarplus.ca.

Although the Company believes that the assumptions and expectations reflected in the forward-looking information are reasonable, there can be no assurance that such information will prove to be accurate, as actual results and future events may differ materially from those anticipated. Accordingly, readers should not place undue reliance on forward-looking information. The forward-looking information contained in this news release is provided to assist investors in understanding the Company’s current expectations, plans and objectives and may not be appropriate for other purposes. The Company undertakes no obligation to update or revise any forward-looking information, except as required by applicable securities laws.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

  • CRB-913 demonstrated statistically significant and clinically meaningful mean weight loss of 5% at 60 mg after 12 weeks with no plateau observed

  • CRB-913 was generally well tolerated with psychiatric adverse events broadly in line with GLP-1 drugs and a favorable emerging GI tolerability profile
     
  • Data support CRB-913’s potential to establish a new class of oral non-incretin obesity medicines

  • Data selected for late-breaking presentation at ObesityWeek® 2026

  • Company will hold an investor call at 8:00am EDT today

NORWOOD, Mass., Sept. 14, 2026 (GLOBE NEWSWIRE) —  Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on new therapies in oncology and obesity, today announced positive topline data from the Company’s CANYON-1 Phase 1b clinical trial of CRB-913 for the treatment of obesity. The data demonstrated statistically significant and clinically meaningful weight loss at all three doses with the 60 mg dose achieving a mean weight loss of 5% at 12 weeks. CRB-913 was associated with a favorable safety profile and fewer gastrointestinal (GI) adverse events based on cross-trial comparison with published data of currently marketed oral GLP-1 drugs. These data support CRB-913’s potential to establish a new class of oral, non-incretin obesity medicines.

“From a clinical practice perspective, a substantial number of patients with obesity either cannot tolerate GLP-1 receptor agonists or do not achieve an adequate therapeutic response,” said Harold Bays, M.D., Medical Director, Louisville Metabolic and Atherosclerosis Research Center/Monroe Biomedical Research, Clinical Associate Professor at the University of Louisville School of Medicine, and an investigator on the CANYON-1 trial. “In addition, more than 60% discontinue treatment within the first year. What I find particularly encouraging about the CANYON-1 study results is that weight reduction had not yet plateaued by the end of the 12-week treatment period, and that CRB-913 appears to have avoided the depressive effects associated with earlier central nervous system-acting cannabinoid receptor agonists. These findings support the potential emergence of the first agent in a new class of obesity medications, offering a novel mechanism of action to help treat the global epidemic of obesity.”

Yuval Cohen, Ph.D., CEO of Corbus Pharmaceuticals, added, “We set out to test a key hypothesis: by successfully designing a peripherally restricted CB1 inverse agonist, can we deliver a safe and tolerable therapeutic alternative with competitive weight loss to oral GLP-1s? The CANYON-1 data provide an important confirmatory milestone of this hypothesis. We are excited about these results and look forward to the Phase 2 study of CRB-913.”

Study Design
The CANYON-1 Phase 1b clinical trial was a 16-week double-blind, placebo-controlled, dose-ranging study that enrolled 254 obese, non-diabetic adult participants at 15 investigational sites in the United States (NCT07310901). The trial included three CRB-913 cohorts of 20 mg, 40 mg, and 60 mg dosed orally once-daily as well as a placebo cohort (randomization of 1:1:1:1). A dose titration regimen was used with all participants receiving CRB-913 commencing at 20 mg/day and then titrating up every two weeks to either 40 mg/day or 60 mg/day depending on their assigned cohort. Participants were dosed for 12 weeks and followed for an additional 4 weeks.

Topline Efficacy
CRB-913 demonstrated rapid, statistically significant and clinically meaningful weight loss at all dose levels, with no evidence of plateauing at any of the doses.

Cohort

Placebo
(n=66)

CRB-913
20 mg (n=65) 40 mg (n=61) 60 mg (n=62)
LS Mean % change in
 weight loss from
baseline at week 121
0.0 % 2.8 % 3.3 % 5.0 %
LS Mean % change in
weight loss at week
121 (placebo adjusted)
NA 2.8 % 3.3 % 5.0 %
p-value vs. placebo NA <0.0001 <0.0001 <0.0001

1 Efficacy estimand. The LS means, and p-values are the Mixed Model for Repeated Measures (MMRM) with percent change from baseline as the dependent variable; sex, treatment group, visit and treatment group-by-visit interaction as categorical fixed effects, and the baseline weight as a covariate. An unstructured covariate matrix is used.

Weight loss response rates were significantly higher across all three CRB-913 cohorts compared to the placebo cohort. All participants who completed the study and received CRB-913 at the 60 mg dose lost weight, with 44.4% losing at least 5.0% from baseline. Similarly, 6.7% of the participants in that cohort lost more than 7.5% of their weight from baseline. The highest recorded weight loss for this cohort was 13.4% from baseline.

Topline Safety and Tolerability2
CRB-913 was generally safe and well tolerated. Treatment discontinuations due to AEs with CRB-913 (3.1%-13.1%) were in line with those recorded with approved oral GLP-1s (6.9%-20.7%) and markedly less than the 13%-42% study discontinuation rate reported with monlunabant.

Psychiatric AEs of Special Interest:
Treatment emergent psychiatric AEs were infrequent, mild to moderate, and transient. There were no serious or severe psychiatric AEs reported in the study. There were no cases of suicidality and only one case of transient depressive symptom (moderate) out of a total of 188 participants dosed with CRB-913. Psychiatric AEs were noted across all cohorts, including placebo, and generally showed no dose-related patterns. The most common psychiatric AE was irritability, and all cases were mild.

Psychiatric AEs were broadly in line with those reported for clinical studies for liraglutide, semaglutide and tirzepatide. The psychiatric AEs were lower than those seen with monlunabant, a recently studied but subsequently discontinued CB1 inverse agonist with significantly higher brain penetration than CRB-913.

Psychiatric Treatment Emergent Adverse Events

  Placebo
(n=66)
CRB-913
20 mg
(n=65)
CRB-913
40 mg
(n=61)
CRB-913
60 mg
(n=62)
Published
data for
liraglutide3,
semaglutide4
and
tirzepatide5
Monlunabant6
Phase 2
(n=180)
Depression 0% 0% 0% 1.6% 2%-4.6% 3%-8%
Anxiety 4.5% 3.1% 8.2% 4.8% 1.9%-7.2% 10%-27%
Irritability 0% 6.2% 8.2% 9.7% Not reported 10%-17%
Insomnia 3.0% 1.5% 4.9% 0% 2.9%-3.9% 7%-17%

2 These limited observations are cross trial comparison derived from separate clinical settings and do not represent head-to-head comparisons. Published safety data reflect adverse events reported over study durations longer than the 12-week CANYON-1 treatment period: 56-week study (liraglutide, Diabetes Obes Metab. 2017), 68-week study (semaglutide, JAMA Intern Med. 2024), and 72-week study (tirzepatide, Obesity 2026).

3 O’Neil et al. “Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials. Diabetes Obes Metab. 2017 (link)

4 Wadden et al. Psychiatric Safety of Semaglutide for Weight Management in People Without Known Major Psychopathology: Post Hoc Analysis of the STEP 1, 2, 3, and 5 Trials. JAMA Intern Med. 2024 (link)

5 Wadden et al, “Psychiatric Safety of Tirzepatide in People With Obesity and No Known Major Psychopathology: A Post Hoc Analysis of SURMOUNT,” Obesity 2026 (link)

6 Knop, F.K. et al. Efficacy and safety of monlunabant in adults with obesity and metabolic syndrome: a double-blind, randomised, placebo-controlled, phase 2a trial. The Lancet 2025 (link) 

Gastrointestinal AEs of Special Interest:
GI AEs were mild or moderate across all CRB-913 doses, with no serious or severe cases reported and were generally not dose-dependent. The emerging GI profile appears more tolerable than the oral GLP-1 class with markedly less vomiting, constipation, and nausea.

Gastrointestinal Treatment Emergent Adverse Events

  CRB-913
(20 mg)
(n=65)
CRB-913
(40 mg)
(n=61)
CRB-913
(60 mg)
(n=62)
Oral
semaglutide
(25 mg)7
Orforglipron
(36 mg
capsule)8
Vomiting 4.6 % 8.2 % 1.6 % 31 % 14% – 28%
Nausea 15.4 % 26.2 % 22.6 % 47 % 41% – 48%
Constipation 4.6 % 1.6 % 4.8 % 20 % 24% – 28%
Diarrhea 21.5 % 26.2 % 22.6 % 18 % 3% –14%

Note: These limited observations are cross trial comparison derived from separate clinical settings and do not represent head-to-head comparisons. Published safety data reflect adverse events reported over study durations longer than the 12-week CANYON-1 treatment period: 68-week study (oral semaglutide 25 mg, N Engl J Med 2025) and 36-week study (orforglipron, N Engl J Med 2023).

7 Wharton, S. et al. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity; N Engl J Med 2025 (Link)

8 Wharton S, et al. Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. N Engl J Med. 2023 (Link). Note: Early clinical development evaluated a 36mg capsule formulation; subsequent bridging established pharmacokinetic bioequivalence to the 17.2mg tablet commercial formulation.

Next Steps
The data from the CANYON-1 Phase 1b trial will be detailed in a late-breaking presentation at ObesityWeek® 2026, to be held November 14 – 17, 2026. The Company plans to engage with the FDA on the clinical development plan and expects to initiate a Phase 2 monotherapy study in the first half of 2027. In addition, the Company is evaluating the potential to combine CRB-913 with GLP-1 therapy.

About Corbus
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focusing on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways. Corbus’ pipeline includes CRB-701, a next-generation antibody drug conjugate for the treatment of Nectin-4-expressing tumors, and CRB-913, an orally delivered highly peripherally restricted CB1 inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com. Connect with us on X, LinkedIn and Facebook.

Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act of 1995, as amended, including those relating to the Company’s trial results, product development, clinical and regulatory timelines, including timing for completion of trials and presentation of data, anticipated timing for initiation of clinical trials, anticipated regulatory interactions and outcomes, including alignment with FDA on trial design, potential accelerated approval, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities, sufficiency of cash runway  and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission including those described in our Annual Report on Form 10-K for the year ended December 31, 2025, and other filings we make with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

All product names, logos, brands and company names are trademarks or registered trademarks of their respective owners. Their use does not imply affiliation or endorsement by these companies.

INVESTOR CONTACTS:
Sean Moran
Chief Financial Officer
Corbus Pharmaceuticals
smoran@corbuspharma.com

Dan Ferry
Managing Director
LifeSci Advisors, LLC
daniel@lifesciadvisors.com

MEDIA CONTACT:
Liz Melone
Founder & Principal
Melone Communications, LLC
liz@melonecomm.com

TORONTO, Sept. 14, 2026 (GLOBE NEWSWIRE) — Belo Sun Mining Corp. (TSX: BSX) (OTCQX: BSXGF) (the “Company” or “Belo Sun”) announced that its wholly-owned Brazilian subsidiary, Belo Sun Mineração Ltda. (“Belo Sun Mineração”), was formally notified on September 11, 2026, of a request for suspension of provisional relief (Suspensão de Tutela Provisória, or “STP”) filed by Brazil’s Federal Public Prosecutor’s Office (“MPF”) before the Brazilian Supreme Court (“STF”), concerning the Installation License (“LI”) for the Company’s Volta Grande Gold Project (the “Project”) in Pará, Brazil.

The STP proceeding (STP 1.156/PA) seeks to immediately suspend the judicial decision issued by the Federal Regional Court of the 1st Region (“TRF-1”) on February 13, 2026, in Interlocutory Appeal No. 1004658-74.2026.4.01.0000, which reinstated the LI and authorized the resumption of regular installation activities. The decision found that the Company had demonstrated compliance with the applicable judicial requirements, including completion of an Indigenous Component Study (“ECI”) based on primary data and consultation under the applicable protocol. The MPF also seeks the continuation of that suspension until a final and non-appealable judgment is rendered in the underlying civil public action concerning the ECI.

STF President Justice Edson Fachin issued an order dated September 2, 2026 and directed Belo Sun Mineração, the State of Pará, the Federal Government, FUNAI and the Municipality of Senador José Porfírio to respond within a common 72-hour deadline. The State of Pará and Belo Sun have already filed their response, requesting that the STP be denied.

Clovis Torres, Chief Executive Officer of Belo Sun commented: “We remain confident in the strength and validity of our Installation License. The TRF-1 court reinstated the license after confirming that we fully satisfied all judicial conditions, including completing the Indigenous Component Study with primary data and carrying out transparent consultations. These are facts which have been previously acknowledged by FUNAI. A STP is an exceptional procedural remedy that requires a showing of a concrete risk of serious harm to public order, health, safety or the economy. As we continue working collaboratively through the conciliation process, we see no basis for such an emergency suspension and will vigorously defend the project and validity of the Installation License.”

The STF is expected to rule on the interim request after receiving the responses from the parties and interested entities formally notified in the proceeding, followed by a submission from the Prosecutor General’s Office.

The LI remains reinstated and in effect while the STF considers the submissions.

About the Company

Belo Sun is a Canadian-based mining company with a portfolio of gold-focused properties in Brazil. The Company is currently focused on the development of the Volta Grande Gold Project. Belo Sun trades on the Toronto Stock Exchange under the symbol “BSX” and on the OTCQX under the symbol “BSXGF”.

For more information, please visit www.belosun.com or contact Investor Relations at info@belosun.com or 1-888-516-4171.

Caution regarding forward-looking information:

This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Forward-looking information includes, but is not limited to, the continued advancement of the Project, the Company’s and interested parties’ responses to the STP filed by the MPF and timelines for responses and rulings imposed by the STF, conciliation process with FUNAI and the ongoing review and update of the Project’s studies. Forward-looking information is based on the opinions and estimates of management as of the date such information is provided, and is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. These factors include, without limitation, actions by the MPF and other parties, rulings or orders of the STF or other courts, changes in the regulatory environment, risks related to the ability of the Company to attract and retain qualified personnel, the ability of the Company to advance the Project to the construction phase, and other risks described in the Company’s filings with Canadian securities regulatory authorities, including the Company’s most recent Annual Information Form. The Company undertakes no obligation to update forward-looking information if circumstances or management’s estimates or opinions should change, except as required by applicable securities laws.

VANCOUVER, British Columbia, Sept. 14, 2026 (GLOBE NEWSWIRE) — Apollo Silver Corp. (“Apollo Silver” or the “Company”) (TSX-V: APGO | OTCQB: APGOF | Frankfurt: 6ZF) today reaffirmed its support for Ejido Benito Juárez (the “Ejido”) in addressing the water challenges that affect agriculture, livestock and livelihoods on its lands in Chihuahua, Mexico. The Company has expressed its commitment to working with the Ejido over the long term on practical solutions to those challenges, beginning with independent technical work on the aquifer, the springs and the existing wells.

“Water is the first question at Ejido Benito Juárez, and it should be,” said Tom Peregoodoff, Executive Chair of Apollo Silver. “The wells and springs of Ejido Benito Juárez have sustained families and their farmland for generations. We have agreed to present the Ejido with a plan outlining our long-term commitment to advancing solutions to their water challenges, including direct support for their agriculture and their livestock.”

The scope, the priorities and the sequencing of the water program will be defined jointly with the Ejido and in accordance with applicable authorizations. The assembly resolution reinstating mineral exploration at Cinco de Mayo is in process; pending that resolution taking effect, Apollo Silver will continue to meet with the community and its representatives ahead of any significant field activity.

Apollo Silver also notes the position of President Claudia Sheinbaum’s administration that mining remains an important contributor to the Mexican economy and that water is to be treated as a right of the communities that depend on it, reflected in the reforms to Mexican water law. The Company believes both propositions can be true at the same time, and intends that community water be part of the resolution wherever it operates.

About Apollo Silver Corp.

Apollo Silver Corp. is a mineral exploration and development company advancing the Calico Silver Project in San Bernardino County, California, and holds an earn-in interest in the Cinco de Mayo Project in Chihuahua, Mexico. The Company is listed on the TSX Venture Exchange under the symbol APGO, on the OTCQB under the symbol APGOF and on the Frankfurt Stock Exchange under the symbol 6ZF.

Please visit www.apollosilver.com for further information.

ON BEHALF OF THE BOARD OF DIRECTORS

Thomas Peregoodoff
Executive Chair

For further information, please contact:

Email: info@apollosilver.com
Telephone: +1 (604) 428-6128

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Statement Regarding “Forward-Looking” Information

This news release includes “forward-looking statements” and “forward-looking information” within the meaning of Canadian securities legislation. All statements included in this news release, other than statements of historical fact, are forward-looking statements including, without limitation, statements with respect to the Company’s intention to work with the Ejido over the long term on practical solutions to water challenges affecting agriculture, livestock and livelihoods; the timing, scope and results of independent technical work on the aquifer, springs and existing wells; the Company’s intention to present the Ejido with a plan outlining its long-term commitment to water solutions and direct support for agriculture and livestock; the anticipated joint definition of the scope, priorities and sequencing of the water program; the timing and outcome of the assembly resolution reinstating mineral exploration at Cinco de Mayo; the Company’s plans to continue meeting with the community and its representatives ahead of any significant field activity; the anticipated interaction between Mexican federal water and mining policy and the Company’s operations; and the Company’s future plans, strategies, and objectives. Forward-looking statements include predictions, projections and forecasts and are often, but not always, identified by the use of words such as “anticipate”, “believe”, “plan”, “estimate”, “expect”, “potential”, “target”, “budget” and “intend” and statements that an event or result “may”, “will”, “should”, “could” or “might” occur or be achieved and other similar expressions and includes the negatives thereof.

Forward-looking statements are based on the opinions and estimates of management as of the date such statements are made and are subject to known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those anticipated, including but not limited to: the outcome and timing of the assembly resolution reinstating mineral exploration at Cinco de Mayo; the ability to reach mutually acceptable arrangements with the Ejido regarding water solutions, or at all; changes in Mexican federal or state water and mining laws or policy; community and stakeholder relations; risks inherent in mineral exploration; uncertainty of mineral resource estimates; fluctuations in commodity prices; regulatory and permitting risks; title risks; and general economic and market conditions. Forward-looking information is based on reasonable assumptions that have been made by the Company as at the date of such information and is subject to known and unknown risks, uncertainties and other factors that may have caused actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking information, including but not limited to: risks associated with mineral exploration and development; metal and mineral prices; availability of capital; accuracy of the Company’s projections and estimates; realization of mineral resource estimates, interest and exchange rates; competition; stock price fluctuations; availability of drilling equipment and access; actual results of current exploration activities; government regulation; political or economic developments; environmental risks; insurance risks; capital expenditures; operating or technical difficulties in connection with development activities; personnel relations; and changes in Project parameters as plans continue to be refined. Forward-looking statements are based on assumptions management believes to be reasonable, including but not limited to the price of silver, gold and barite; the demand for silver, gold and barite; the ability to carry on exploration and development activities; the timely receipt of any required approvals; the ability to obtain qualified personnel, equipment and services in a timely and cost-efficient manner; the ability to operate in a safe, efficient and effective matter; and the regulatory framework regarding environmental matters, and such other assumptions and factors as set out herein. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate and actual results, and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward looking information contained herein, except in accordance with applicable securities laws. The forward-looking information contained herein is presented for the purpose of assisting investors in understanding the Company’s expected financial and operational performance and the Company’s plans and objectives and may not be appropriate for other purposes. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws.

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.